Furthermore, around 50% of cases showed KRAS and/or NRAS mutations for each category of tumor cell content (27/54 in cases with <10% tumor cell content; 278/553 in those with 10–50% tumor cells; or 59/117 in cases with >50% tumor cells). This evidence concerns the gene KRAS and neoplasm.